News

Two oncology nurses with Allegheny Health Network discuss how they guide patients through their diagnosis, treatment, and life after cancer.

The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.

Patients with cancer were reported to have mixed expectations with immunotherapy as part of their oncology treatment.

The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.

A patient-friendly stoplight tool with 3 different colored zones helped patients undergoing chemotherapy manage diarrhea and reduce hospital and emergency department visits.

Patients who receive medical cannabis in addition to standard opioids may require less overall opioid treatment to manage their pain.

Independent verification of documentation is paramount to patient safety.

An implementation of nursing practice changes helped improve the fall rates among patients being treated by the surgical oncology team.

Laura Zitella, MS, RN, ACNP-BC, AOCN, reviews a case study where a 52-year-old female patient with metastatic colorectal carcinoma begins experiencing diffuse abdominal pain.

Very low dose radiation therapy was found to be an effective treatment approach in the palliative setting for patients with indolent non-Hodgkin lymphoma.

Oncology nurses are in less control of their communication environment compared with other health care providers; however, certain strategies can help them communicate effectively with their patients.

At the 47th Annual ONS Congress, CURE® Media group honored oncology nurses at their 2022 Extraordinary Healer® Award ceremony.

The most important thing that an oncology nurse can do to help a patient navigate their sexual health is repeatedly offer them permission to have conversations surrounding their health.

Patients with relapsed/refractory large B-cell lymphoma continued to derive benefit from lisocabtagene maraleucel after 2 years of follow-up.

Patients with relapsed or refractory large B-cell lymphoma experienced improved overall survival following treatment with axicabtagene ciloleucel.

Belimumab has emerged as a safe and tolerable agent that may be useful for the prophylaxis of chronic graft-vs-host-disease.

An oncology social worker reflects on a day in the life and how the memory of her sister motivates her to tackle her work.

The phase 3 RATIONALE 309 trial highlighted the combined efficacy of tislelizumab and chemotherapy in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

Advocacy and opposition continue to grow regarding the National Organization of Nurse Practitioner Faculties’ goal of requiring the Doctor of Nursing Practice degree (DNP) for entry-level nurse practitioners.

Adding the immunotherapy to chemotherapy in the frontline setting may improve overall survival for patients with advanced biliary tract cancer.

Journaling may help patients with sarcoma feel more in control of their symptoms and communicate better with their care team.

Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.

A long-term analysis of the phase 3 BILCAP study highlighted modest benefit for patients with resected biliary tract cancer who received capecitabine following surgery.

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.

Fixing the problem will involve holding medical institutions accountable for addressing implicit bias among providers.

An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.